The Relationship Between The Occurrence Of Prostate Cancer And Obesity And Blood Lipid

Objective:To explore the relationship between the occurrence of prostate cancer and obesity and blood lipids,explore the possibility of obesity and blood lipids affecting the risk score of prostate cancer,provide reliable data for the study of the correlation between prostate cancer and obesity,and provide reference for clinical decision-making of prostate cancer.Methods:A retrospective analysis was made of the medical records of patients who underwent transrectal prostate biopsy under the guidance of B-ultrasound from January 2018 to December 2018 in the Second Affiliated Hospital of Kunming Medical University.Detailed data of patients and pathological reports of puncture results were collected through data management system of Ultrasound Intervention Department of the Second Affiliated Hospital of Kunming Medical University and electronic case system of the Second Affiliated Hospital of Kunming Medical University.Data analysis software SPSS.20 was used to compare the collected data among groups,logistic regression analysis of influencing factors,Spearman grade correlation analysis,P<0.05,the difference was statistically significant.Results:1.A total of 258 patients underwent ultrasound-guided transrectal prostate biopsy.Postoperative pathology revealed 121 cases(46.9%)of prostate cancer and 137 cases(53.1%)of non-prostate cancer.Relevant interference factors were excluded and 207 cases were included in the study group,including 104 cases(50.2%)of prostate cancer and 103 cases(49.8%)of non-prostate cancer.2.The mean age and median PSA of prostate cancer group were higher than those of non-prostate cancer group,and there was significant difference between the two groups(P<0.05).There was no significant difference in height,weight,body mass index(BMI),cholesterol,triglyceride,high(low)density lipoprotein,lipid a,apolipoprotein A1 and apolipoprotein B between prostate cancer group and non-prostate cancer group(P<0.05).>0.05).3.Compared with non-prostate cancer group,the proportion of obesity(BMI(>25 kg/m2)and high cholesterol in prostate cancer group was significantly higher(P<0.05),and there was no significant difference in high triglyceride,high and low density lipoprotein,low and high density lipoprotein(P>0.05).Multivariate logistic regression analysis showed that age,PSA,obesity and high cholesterol were independent risk factors for prostate cancer.5.There were significant differences in PSA,obesity and apolipoprotein A1 between high-risk group of prostate cancer(Gleason score(>8)and non-high-risk group of prostate cancer(Gleason score<8)(P<0.05);there were no differences in height,weight,body mass index,cholesterol,triglyceride,high(low)density lipoprotein,lipid a,apolipoprotein A1 and apolipoprotein B values.The significance of accounting(P>0.05).6.The multiple logistic regression analysis showed that obesity and PSA were independent risk factors,and apolipoprotein A1 was a protective factor for high-risk prostate cancer.7.The correlation analysis of clinical TNM stage,Gleason grade and PSA grade with Spearman grade of obesity and blood lipid showed that clinical TNM stage was negatively correlated with high density lipoprotein and apolipoprotein Al,while Gleason grade was positively correlated with BMI and negatively correlated with apolipoprotein A1.Conclusion(s):].Age,PSA,obesity and high cholesterol are independent risk factors for prostate cancer,but triglyceride,high(low)density lipoprotein,lipid A and apolipoprotein are not risk factors for prostate cancer.2.Obesity and PSA are independent risk factors for high-risk prostate cancer.Apolipoprotein Al is a protective factor for high-risk prostate cancer.Cholesterol,triglyceride,high(low)density lipoprotein,lipid A and apolipoprotein B are not independent risk factors for high-risk prostate cancer.3.Clinical TNM stage was negatively correlated with high density lipoprotein and apolipoprotein A1;Gleason score was positively correlated with BMI and negatively correlated with apolipoprotein A1.